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Background: The development of cardiogenic shock (CS) after a STEMI is associated with high rates of mortality. Rapid, complete and sustained 
reperfusion of the infarct related artery has been shown to improve mortality in patients with AMI. However, in real-life clinical practice, it is unclear 
what outcomes are associated with patients who develop CS due to a STEMI.
Methods:  The University of Ottawa Heart Institute has developed a citywide protocol in which all patients who present with STEMI are treated 
with primary PCI (PPCI) at one cardiac center. Consecutive patients who developed CS post STEMI and who were treated with PPCI were identified. 
We sought to identify the incidence of CS in a dedicated, citywide protocol. We also assessed the differences in baseline characteristics and clinical 
outcomes for patients with and without CS. Patients were defined as having CS if they had a systolic blood pressure < 80mmHG which did not 
respond to fluid expansion, and required the use of intravenous inotropic support or the use of intra-aortic balloon counterpulsation.
Results:  Of 1798 patients presenting between 07/01/2004 - 11/30/2009 for PPCI, 150 (8%) developed CS while in hospital. Patients who 
developed CS had a higher incidence of diabetes mellitus, hypertension, previous MI, previous CVA. Five patients did not have PCI attempted. Post-
procedure TIMI grade 3 was reported in 1492/1623 (92%) of the non CS patients and in 106/147 (72%) of the CS patients (p<0.0001). The door 
to balloon time was 98 and 116 minutes in the non CS and CS groups, respectively (p<0.001). Patients who developed CS accounted for 72% of 
patient deaths. The in-hospital mortality rate for non CS patients was 1.5% and 43.3% for CS patients (p<0.0001).
Conclusion: The incidence of CS in a dedicated, citywide PPCI program is similar to rates reported from PCI studies elsewhere. The baseline 
characteristics of the two groups are distinct and predictive of patients’ clinical outcomes. The mortality at all time points in the CS group remains 
elevated in a real-life treatment situation. This supports the need for continued improvements in door-to-balloon times, as well as, increased 
awareness of dangerous cardiac symptoms amongst the general population. 
